VBI Vaccines Announces PreHevbri Is Now Available In The United Kingdom For The Prevention Of Hepatitis B In Adults
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines announced that its 3-antigen hepatitis B vaccine, PreHevbri, is now available in the UK for adults. The vaccine will be launched through a marketing and distribution partnership with Valneva.
June 15, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VBI Vaccines' PreHevbri is now available in the UK, marking the first European market launch of the 3-antigen hepatitis B vaccine.
The availability of PreHevbri in the UK marks the first European market launch for VBI Vaccines' 3-antigen hepatitis B vaccine. This is a significant milestone for the company and is expected to have a positive short-term impact on its stock price. The partnership with Valneva for marketing and distribution further strengthens the potential for success in the European market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100